Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas

Andrew Kaz, Young Ho Kim, Slavomir Dzieciatkowski, Henry T. Lynch, Patrice Watson, Mary Kay Washington, Li Lin, William M. Grady

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Colorectal cancer (CRC) forms through a series of histologic steps that are accompanied by mutations and epigenetic alterations, which is called the polyp-cancer sequence. The role of epigenetic alterations, such as aberrant DNA methylation, in the polyp-cancer sequence in sporadic CRC and particularly in hereditary colon cancer is not well understood. Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14ARF in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit" mechanism in CRC and to characterize the role of DNA methylation in the polyp phase of the Lynch syndrome. We found MLH1 and p14ARF are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. Therefore, the frequency and pattern of gene methylation varies between the Lynch syndrome and sporadic colon adenomas, implying differences in the molecu-lar pathogenesis of the tumors. MLH1 methylation in the Lynch syndrome adenomas suggests gene methylation might have a role in the initiation of these neoplasms.

Original languageEnglish
Pages (from-to)1922-1929
Number of pages8
JournalInternational Journal of Cancer
Volume120
Issue number9
DOIs
StatePublished - May 1 2007

Fingerprint

Hereditary Nonpolyposis Colorectal Neoplasms
DNA Methylation
Adenoma
Methylation
Polyps
Tumor Suppressor Protein p14ARF
Colorectal Neoplasms
Epigenomics
Colonic Neoplasms
Neoplasms
Mutation
Gene Frequency
Colon

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Kaz, A., Kim, Y. H., Dzieciatkowski, S., Lynch, H. T., Watson, P., Washington, M. K., ... Grady, W. M. (2007). Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. International Journal of Cancer, 120(9), 1922-1929. https://doi.org/10.1002/ijc.22544

Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. / Kaz, Andrew; Kim, Young Ho; Dzieciatkowski, Slavomir; Lynch, Henry T.; Watson, Patrice; Washington, Mary Kay; Lin, Li; Grady, William M.

In: International Journal of Cancer, Vol. 120, No. 9, 01.05.2007, p. 1922-1929.

Research output: Contribution to journalArticle

Kaz, A, Kim, YH, Dzieciatkowski, S, Lynch, HT, Watson, P, Washington, MK, Lin, L & Grady, WM 2007, 'Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas', International Journal of Cancer, vol. 120, no. 9, pp. 1922-1929. https://doi.org/10.1002/ijc.22544
Kaz, Andrew ; Kim, Young Ho ; Dzieciatkowski, Slavomir ; Lynch, Henry T. ; Watson, Patrice ; Washington, Mary Kay ; Lin, Li ; Grady, William M. / Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas. In: International Journal of Cancer. 2007 ; Vol. 120, No. 9. pp. 1922-1929.
@article{acee011a384d4a98ac11b5dd874ea90e,
title = "Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas",
abstract = "Colorectal cancer (CRC) forms through a series of histologic steps that are accompanied by mutations and epigenetic alterations, which is called the polyp-cancer sequence. The role of epigenetic alterations, such as aberrant DNA methylation, in the polyp-cancer sequence in sporadic CRC and particularly in hereditary colon cancer is not well understood. Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14ARF in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a {"}second hit{"} mechanism in CRC and to characterize the role of DNA methylation in the polyp phase of the Lynch syndrome. We found MLH1 and p14ARF are methylated in 53 and 60{\%} of the Lynch syndrome adenomas and in 4 and 20{\%} of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14{\%} of the Lynch syndrome adenomas versus 50 and 64{\%} of sporadic adenomas. Therefore, the frequency and pattern of gene methylation varies between the Lynch syndrome and sporadic colon adenomas, implying differences in the molecu-lar pathogenesis of the tumors. MLH1 methylation in the Lynch syndrome adenomas suggests gene methylation might have a role in the initiation of these neoplasms.",
author = "Andrew Kaz and Kim, {Young Ho} and Slavomir Dzieciatkowski and Lynch, {Henry T.} and Patrice Watson and Washington, {Mary Kay} and Li Lin and Grady, {William M.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1002/ijc.22544",
language = "English",
volume = "120",
pages = "1922--1929",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Evidence for the role of aberrant DNA methylation in the pathogenesis of Lynch syndrome adenomas

AU - Kaz, Andrew

AU - Kim, Young Ho

AU - Dzieciatkowski, Slavomir

AU - Lynch, Henry T.

AU - Watson, Patrice

AU - Washington, Mary Kay

AU - Lin, Li

AU - Grady, William M.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Colorectal cancer (CRC) forms through a series of histologic steps that are accompanied by mutations and epigenetic alterations, which is called the polyp-cancer sequence. The role of epigenetic alterations, such as aberrant DNA methylation, in the polyp-cancer sequence in sporadic CRC and particularly in hereditary colon cancer is not well understood. Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14ARF in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit" mechanism in CRC and to characterize the role of DNA methylation in the polyp phase of the Lynch syndrome. We found MLH1 and p14ARF are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. Therefore, the frequency and pattern of gene methylation varies between the Lynch syndrome and sporadic colon adenomas, implying differences in the molecu-lar pathogenesis of the tumors. MLH1 methylation in the Lynch syndrome adenomas suggests gene methylation might have a role in the initiation of these neoplasms.

AB - Colorectal cancer (CRC) forms through a series of histologic steps that are accompanied by mutations and epigenetic alterations, which is called the polyp-cancer sequence. The role of epigenetic alterations, such as aberrant DNA methylation, in the polyp-cancer sequence in sporadic CRC and particularly in hereditary colon cancer is not well understood. Consequently, we assessed the methylation status of CDKN2A/p16, MGMT, MLH1 and p14ARF in adenomas arising in the Lynch syndrome, a familial colon cancer syndrome caused by MLH1 and MSH2 mutations, to determine if DNA methylation is a "second hit" mechanism in CRC and to characterize the role of DNA methylation in the polyp phase of the Lynch syndrome. We found MLH1 and p14ARF are methylated in 53 and 60% of the Lynch syndrome adenomas and in 4 and 20% of sporadic adenomas, whereas CDKN2A/p16 and MGMT are methylated in 6 and 14% of the Lynch syndrome adenomas versus 50 and 64% of sporadic adenomas. Therefore, the frequency and pattern of gene methylation varies between the Lynch syndrome and sporadic colon adenomas, implying differences in the molecu-lar pathogenesis of the tumors. MLH1 methylation in the Lynch syndrome adenomas suggests gene methylation might have a role in the initiation of these neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=33947218541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947218541&partnerID=8YFLogxK

U2 - 10.1002/ijc.22544

DO - 10.1002/ijc.22544

M3 - Article

C2 - 17278092

AN - SCOPUS:33947218541

VL - 120

SP - 1922

EP - 1929

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -